drug

avapritinib

Marketedupdated 2mo ago

by Blueprint Medicines Corp

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 9, 2027

186 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (29)

Mar 8, 2042method-of-use (U-2726)US 12060354
Mar 8, 2042method-of-use (U-2726)US 12060354
Mar 8, 2042method-of-use (U-2726)US 12060354
Apr 10, 2040compositionUS 11964980
Apr 10, 2040compositionUS 11964980
Apr 10, 2040compositionUS 11964980
Apr 10, 2040compositionUS 11964980
Apr 10, 2040compositionUS 11964980
Apr 10, 2040method-of-use (U-3168)US 11999744
Apr 10, 2040method-of-use (U-3168)US 11999744
Apr 10, 2040method-of-use (U-3506)US 11999744
Apr 10, 2040method-of-use (U-3168)US 11999744
Apr 10, 2040method-of-use (U-3506)US 12252494
Oct 15, 2034compositionUS 11827642
Oct 15, 2034compositionUS 9200002
Oct 15, 2034compositionUS 9200002
Oct 15, 2034compositionUS 9200002
Oct 15, 2034compositionUS 9200002
Oct 15, 2034compositionUS 9200002
Oct 15, 2034compositionUS 9944651
Oct 15, 2034compositionUS 9944651
Oct 15, 2034compositionUS 9944651
Oct 15, 2034compositionUS 9944651
Oct 15, 2034compositionUS 9944651
Oct 15, 2034compositionUS 9994575
Oct 15, 2034compositionUS 9994575
Oct 15, 2034compositionUS 9994575
Oct 15, 2034compositionUS 9994575
Oct 15, 2034compositionUS 9994575

FDA exclusivities (16)

May 22, 2030ODE-434Orphan Drug (7y)3.9y
May 22, 2030ODE-434Orphan Drug (7y)3.9y
May 22, 2030ODE-434Orphan Drug (7y)3.9y
May 22, 2030ODE-434Orphan Drug (7y)3.9y
May 22, 2030ODE-434Orphan Drug (7y)3.9y
Jun 16, 2028ODE-356Orphan Drug (7y)1.9y

Data sources

ClinicalTrials.gov

last refreshed just now

Found something off?

Jun 16, 2028ODE-356Orphan Drug (7y)1.9y

Jan 9, 2027ODE-366Orphan Drug (7y)186d

May 22, 2026I-912Indication (3y)

Trials studying avapritinib

phase2(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosiscompletedn=107
—A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germanyrecruitingn=80
phase1Avapritinib With Decitabine in Patients With SM-AHNrecruitingn=34
—Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real Worldcompletedn=61
phase4Avapritinib Rollover Studyrecruitingn=60
phase2A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signalingcompletedn=29
phase2(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosisactive not recruitingn=251
phase1A Drug-drug Interaction Study of Avapritinib and Midazolamcompletedn=10

more trials →